Antigens of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor 1: Correlates in Nonsmoking Japanese and Caucasian Men and Women

Summary

We reported in a 1987 preliminary study that tissue plasminogen activator antigen was significantly higher in American Caucasian men than in Japanese men. To further examine possible differences in fibrinolytic activity between the two races, an expanded study was conducted in a total of 300 nonsmoking men and women aged 47-69 years in two population-based samples: rural Japanese living in Akita and Caucasians living in Minneapolis-St. Paul, MN. Antigens of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) were measured. Mean t-PA antigen was 2.3 ng/ml higher in Caucasian men than in Japanese men (P <0.001), but no race difference was seen for women (P = 0.59). Mean PAI-1 was higher in Caucasians than in Japanese for both sexes, and the race difference in mean was 1.8 ng/ml for men (P = 0.07) and 4.4 ng/ml for women (P <0.001). Both t-PA and PAI-1 were associated positively with body mass index and blood triglycerides for all sex-race groups, and positively with alcohol intake for Japanese and Caucasian men. Compared to Japanese, Caucasians of both sexes had higher levels of body mass index and blood triglycerides, and lower average intake of alcohol among men. Even when adjusted for body mass index, triglycerides, alcohol and other cardiovascular risk factors, the race difference in mean t-PA antigen persisted for men (P <0.001), as did the difference in mean PAI-1 for men (P = 0.03) and women (P = 0.001). If PAI-1 is a risk factor for coronary heart disease, a higher level in Caucasians than Japanese would correspond to the higher mortality rate from coronary heart disease in the United States than in Japan.

• References

• 1 Juhan-Vague I, Moerman B, De Cock F, Aillaud MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523-530
• 2 Hamsten A, Wiman B, De Faire U, Blombäck M. Increased plasma levels of rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563
• 3 Paramo JA, Colucci M, Collen D. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 1985; 291: 573-574
• 4 Gram J, Kluft C, Jespersen J. Depression of tissue plasminogen activator (t-PA) activity and rise of t-PA inhibition and acute phase reactants in blood of patients with acute myocardial infarction (AMI). Thromb Haemostas 1987; 58: 817-821
• 5 Nilsson TK, Johnson O. The extrinsic fibrinolytic system in survivors of myocardial infarction. Thromb Res 1987; 48: 621-630
• 6 Kruithof EKO, Gudinchet A, Bachmann F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemostas 1988; 59: 7-12
• 7 Korninger C, Jäger R, Huber K, Lechner K. Levels of plasminogen activator inhibitor in patients with angina pectoris. Klin-Wochenschr 1988; 66 (Suppl. 12) 59-61
• 8 Olofsson BO, Dahlen G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989; 10: 77-82
• 9 Huber K, Rosc D, Resch I, Schuster E, Glogar DH, Kaindl F, Binder BR. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Thromb Haemostas 1988; 60: 372-376
• 10 O’Connor NTJ, Cederholm-Williams S, Copper S, Cotter L. Hypercoagulability and coronary artery disease. Br Heart J 1984; 52: 614-616
• 11 Francis RB, Kawanishi D, Baruch T, Mahrer P, Rahimtoola S, Feinstein DI. Impaired fibrinolysis in coronary artery disease. Am Heart J 1988; 4: 776-780
• 12 Estellés A, Tormo G, Aznar J, Espãna F, Tormo V. Reduced fibrinolytic activity in coronary heart disease in basal conditions and after exercise. Thromb Res 1985; 40: 373-383
• 13 Collen D, Juhan-Vague I. Fibrinolysis and atherosclerosis. Semin Thromb Hemostas 1988; 14: 180-183
• 14 Hamsten A, De Faire U, Walldius G, Dahlén G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; ii: 3-9
• 15 Pisa Z, Uemura K. Trends of mortality from ischaemic heart disease and other cardiovascular diseases in 27 countries, 1968-1977. World Health Stat Q 1982; 35: 11-47
• 16 Keys A. Summary: Coronary heart disease in seven countries. Circulation 1970; (Suppl. 01) 42: 186-198
• 17 Iso H, Folsom AR, Wu KK, Finch A, Sato S, Munger RG, Shimamoto T, Terao A, Komachi Y. Hemostatic variables in Japanese and Caucasian men. Tissue plasminogen activator, antithrombin III, and protein C and their relations to coronary risk factors. Am J Epidemiol 1990; 132: 41-46
• 18 ARIC Investigators. The Atherosclerosis Risk in Communities(ARIC) Study: design and objectives. Am J Epidemiol 1989; 129: 687-702
• 19 Haire WD, Goldsmith JC, Rasmussen J. Abnormal fibrinolysis in healthy male cigarette smokers: role of plasminogen activator inhibitors. Am J Hematol 1989; 31: 36-40
• 20 Sundell IB, Nilson TK, Ranby M, Hallmans G, Hellsten G. Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: a cross-sectional study in Norsjo, Sweden. J Clin Epidemiol 1989; 42: 719-723
• 21 Meade TW, Imerson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischemic heart disease. Lancet 1987; ii: 986-988
• 22 National Heart, Lung and Blood Institute. ARIC Manuals of Operations. 7. Blood Collection and Processing; 8. Lipid and Lipoprotein Determination; 9. Hemostasis Determinations. Chapel Hill, NC, ARIC Coordinating Center, School of Public Health. University of North Carolina; 1987
• 23 Grimaudo V, Hauert J, Bachmann F, Kruithof EKO. Diurnal Variation of the fibrinolytic system. Thromb Haemostas 1988; 59: 495-499
• 24 Kluft C, Jie AFH, Rijken DC, Verheijen JH. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1). Thromb Haemostas 1988; 59: 329-332
• 25 Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983; 29: 1075-1080
• 26 Nagele U, Hagele EO, Sauer G, Wiedemann E, Lehmann P, Wahlefeld AW, Gruber W. Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency. J Clin Chem Biochem 1984; 22: 165-174
• 27 Manual of Laboratory Operations, Lipid Research Clinics Program: Lipid and Lipoprotein Analysis. Bethesda, MD, US Department of Health and Welfare Publication 1974; 1: 75-628
• 28 Warnick GR, Benderson JM, Albers JJ. Quantization of high-density-lipoprotein subclasses after separation by dextran sulfate and MG²⁺ precipitation (Abstract). Clin Chem 1982; 28: 1574
• 29 Nakamura M, Morita M, Yabuuchi E, Yukami M, Kuruma S, Kuritani C, Kanatsu Y, Nishiwaki E, Ueshima H, Iida M, Komachi Y. The evaluation and the results of cooperative cholesterol and triglyceride Standardization program by WHO-CDC. Rinsho Byori 1982; 30: 325-332 (in Japanese)
• 30 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
• 31 Cloey T, Bachorik PS, Becker D, Finney C, Lowry D, Sigmund W. Reevaluation of serum-plasma differences in total cholesterol concentrations. JAMA 1990; 263: 2788-2789
• 32 Kirkendall WM, Feinlieb M, Freis ED, Mark AL. Recommendations for human blood pressure determination by Sphygmomanometers. Subcommittee of the AHA Postgraduate Education Committee. Circulation 1980; 62: 1146A-1155A
• 33 De Gaudemaris R, Folsom AR, Prineas RJ, Luepker RV. The random-zero versus the standard mercury sphygmomanometer: a systematic blood pressure difference. Am J Epidemiol 1985; 121: 282-290
• 34 Owan I, Suda T. Strategy of osteoporosis therapy. J Clin Exp Med (IGAKU NO AYUMI) 1992; 160: 115-117 (in Japanese)
• 35 Iso H, Sato S, Folsom AR, Shimamoto T, Terao A, Munger RG, Kitamura A, Konishi M, Iida M, Komachi Y. Serum fatty acids and fish intake in rural Japanese, urban Japanese, Japanese American and Caucasian American men. Int J Epidemiol 1989; 18: 374-381
• 36 Keys A. The diet: Coronary heart disease in seven countries. Circulation 1970; 42 (Suppl. 01) 162-183
• 37 Iso H, Folsom AR, Wu KK, Finch A, Munger RG, Sato S, Shimamoto T, Terao T, Komachi Y. Hemostatic variables in Japanese and Caucasian men. Plasma fibrinogen, factor VIIc, factor VIIIc, and von Willebrand factor and their relations to cardiovascular disease risk factors. Am J Epidemiol 1989; 130: 925-934
• 38 Crutchley DJ, McPhee GV, Terris MF, Canossa-Terris MA. Levels of three hemostatic factors in relation to serum lipids. Monocyte procoagulant activity, tissue plasminogen activator, and type-1 plasminogen activator inhibitor. Arteriosclerosis 1989; 9: 934-939
• 39 Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987; 9: 263-268
• 40 Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, Altan C. Relationships between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabete Metab 1987; 13: 331-336
• 41 Veenstra J, Te Wierik E, Kluft C. Alcohol and fibrinolysis. Fibrinolysis 1990; 4 (Suppl. 02) 64-68
• 42 Refsum N, Olsen H, Østerud B. Drinking beer increases whole blood clot lysis time and plasma tissue plasminogen activator antigen (abstract). Thromb Haemostas 1991; 65: 1269
• 43 Kluft C, Veenstra J, Schaafsma G, Pikaar NA. Regular moderate wine consumption for five weeks increases plasma activity of the plasminogen activator inhibitor-1 (PAI-1) in healthy young volunteers. Fibrinolysis 1990; 4 (Suppl. 02) 69-70
• 44 Dyer AR, Stamler J, Paul O, Lepper M, Shekelle RB, McKean H, Garside D. Alcohol consumption and 17-year mortality in the Chicago Western Electric Company Study. Prev Med 1980; 9: 78-90
• 45 Gordon T, Kannel WB. Drinking habits and cardiovascular disease: The Framingham Study. Am Heart J 1983; 105: 667-673
• 46 Moore RD, Pearson T. Moderate alcohol consumption and coronary artery disease; a review. Medicine 1986; 65: 242-267
• 47 MeaDe TW, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet 1987; ii: 986-988
• 48 Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 191-205
• 49 Kruithof EKO, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: Development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70: 1645-1653
• 50 Korninger C, Speiser W, Wojta J, Binder BR. Sandwich ELISA for t-PA antigen employing a monoclonal antibody. Thromb Res 1986; 41: 527-535
• 51 Takada Y, Takada A. Plasma levels of t-PA, free PAI-1 and a complex of t-PA with PAI-1 in human males and females at various ages. Thromb Res 1989; 55: 601-609
• 52 Gevers LeuvenJA, Kluft C, Bertina RM, Hessel LW. Effects of two low-dose oral contraceptives on circulating components of the coagulation and fibrinolytic systems. J Lab Clin Med 1987; 109: 631-636
• 53 Rijken DC. Relationships between structure and function of tissue-type plasminogen activator. Klin Wochenschr 1988; 66 (Suppl. 12) 33-39
• 54 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 69: 381-387
• 55 Urano T, Sumiyoshi K, Pietraszek MH, Takada Y, Takada A. PAI-1 plays an important role in the expression of t-PA activity in the euglobulin clot lysis by coijtrolling the concentration of free t-PA. Thromb Haemostas 1991; 66: 474-478
• 56 Bergsdorf N, Nilsson T, Wallen P. An enzyme linked immunosorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic disease. Thromb Haemostas 1983; 50: 740-744